000			02687nam a22003497a 4500
008			221213s20222022 xxu||||| |||| 00| 0 eng d
022			_a0960-9776
024			_a10.1016/j.breast.2022.10.008 [doi]
024			_aPMC9663523 [pmc]
024			_aS0960-9776(22)00173-4 [pii]
040			_aOvid MEDLINE(R)
099			_a36375387
245			_aTrastuzumab-based regimens beyond progression: A crucial treatment option for HER2+ advanced/metastatic breast cancer.
251			_aBreast. 66:262-271, 2022 Oct 18.
252			_aBREAST. 66:262-271, 2022 Oct 18.
253			_aBreast (Edinburgh, Scotland)
260			_c2022
260			_fFY2023
260			_p2022 Oct 18
265			_saheadofprint
266			_d2022-12-13
520			_aUpon its establishment for the treatment of metastatic breast cancer (mBC), continuing trastuzumab beyond disease progression was an important paradigm shift that became the recommendation by major guidelines. However, data supporting continuation of human epidermal growth factor receptor 2 (HER2) blockade with trastuzumab beyond the second-line setting are limited, resulting in a lack of approval of, or access to, this therapeutic strategy in many countries. This study aimed to provide additional data on the continued use of trastuzumab and trastuzumab-based therapies in combination with chemotherapy (CT) as third-line treatment for patients with mBC. This open-cohort, retrospective, observational study used deidentified patient-level data from an electronic health record-derived database that included patients with mBC who initiated third-line treatment with trastuzumab-based therapy combined with CT (Tras + CT; n = 288) or CT alone (CT; n = 49). Patients who received Tras + CT had a longer weighted median overall survival vs those who received CT only: 20.6 months (95% CI, 18.3-26.4 months) vs 10.1 months (95% CI, 7.8-12.3 months), respectively (hazard ratio [HR], 0.29; 95% CI, 0.16-0.53). This study provides additional support for maintaining trastuzumab-based therapies for patients with HER2+ mBC beyond second-line treatment. This treatment option should be available for all patients with mBC worldwide. Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.
546			_aEnglish
650			_aIN PROCESS -- NOT YET INDEXED
656			_aAssociate Dean for Research Development
656			_aMedStar Health
657			_aJournal Article
700			_aSwain, Sandra M _bMSH
790			_aCardoso F, Mouta J, Ross R, Sanglier T, Shi T, Swain S
856			_uhttps://dx.doi.org/10.1016/j.breast.2022.10.008 _zhttps://dx.doi.org/10.1016/j.breast.2022.10.008
942			_cART _dArticle
999			_c47 _d47